Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07034261

Enrollment

Registered

2025-06-24

Start date

2026-09-01

Completion date

2027-09-01

Last updated

2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes

Keywords

CGM Device

Brief summary

The aim of this study is to determine the ability of postpartum continuous glucose monitoring (CGM) for subjects with gestational diabetes (GDM) to predict dysglycemia on 4-12 week postpartum oral glucose tolerance test (OGTT).

Detailed description

Gestational diabetes (GDM) is glucose intolerance that develops during pregnancy. In the US, GDM affected 8.3% of pregnancies in 2021. Persistent glucose intolerance is present in up to 20% of women at post-partum follow up and subsequent risk for type 2 diabetes is significantly increased. All patients with GDM should undergo post-partum oral glucose tolerance test (OGTT) at 4-12 weeks to identify persistence glucose intolerance or overt diabetes. Detecting postpartum dysglycemia in people with GDM is a critical step for reducing long-term risk of type 2 diabetes and its associated complications. However, \<50% of people complete the postpartum OGTT due to barriers in transportation, finances, and childcare. Recent studies have examined the use of postpartum continuous glucose monitoring (CGM) and proposed CGM metrics to predict dysglycemia on postpartum OGTT in people with GDM. These findings should be validated in other cohorts to confirm broad applicability. This pilot study aims to enroll subjects with GDM at the University of Chicago to wear a blinded CGM for 14 days postpartum (study intervention) and then complete a OGTT at 4-12 weeks postpartum (standard of care).

Interventions

DEVICEBlinded Continuous Glucose Monitoring Device

Subjects will be asked to wear blinded continuous glucose monitoring device for 14 days.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age greater than or equal to 18 2. Completed pregnancy with delivery of a live born infant(s). Pregnancies with multiple gestations will be included 3. No prior history of type 1 or type 2 diabetes \* Patients with a history of gestational diabetes (GDM) in a prior pregnancy will be eligible for inclusion. 4. GDM diagnosis by standard screening at 24-28 weeks * 2 hour 75g oral glucose tolerance test (OGTT); one abnormal value required for diagnosis * Fasting glucose 92 * 1 hour 180 * 2 hour 153 * 3 hour 100g OGTT - two abnormal values required for diagnosis * Fasting glucose - 95 * 1 hour 180 * 2 hour 155 * 3 hour 140 There are no

Exclusion criteria

for this study. Eligibility will be based on inclusion criteria.

Design outcomes

Primary

Measure	Time frame	Description
Determine the ability of continuous glucose monitoring to predict dysglycemia	baseline to Day 70	Assess the validity of the continuous glucose monitoring metrics (percentage) proposed by Cabrera et al. (percent time \>180 of \>4%)

Contacts

CONTACTLaura Dickens, MD

ldickens1@bsd.uchicago.edu773-795-0460

PRINCIPAL_INVESTIGATORLaura Dickens, MD

University of Chicago

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 12, 2026